Treatment of Psoriasis by the Topical Application of the Novel Cholecalciferol Analogue Calcipotriol (MC 903)
- 1 December 1989
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 125 (12) , 1647-1652
- https://doi.org/10.1001/archderm.1989.01670240047011
Abstract
From JAMA Dermatology — Treatment of Psoriasis by the Topical Application of the Novel Cholecalciferol Analogue Calcipotriol (MC 903)This publication has 10 references indexed in Scilit:
- Improvement of psoriasis by a topical vitamin D3 analogue (MC 903) in a double-blind studyBritish Journal of Dermatology, 1988
- 1α,25-Dihydroxyvitamin D3 and a novel vitamin D analogue MC 903 are potent inhibitors of human interleukin 1 in vitroImmunology Letters, 1988
- Effects of a novel vitamin D analogue MC 903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivoBiochemical Pharmacology, 1988
- Synthesis of mc 903, a biologically active vitamin D metabolite analogueTetrahedron, 1987
- Effect of 1α,25-Dihydroxyvitamin D3 on the Morphologic and Biochemical Differentiation of Cultured Human Epidermal Keratinocytes Grown in Serum-Free ConditionsJournal of Investigative Dermatology, 1986
- Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol).Journal of Clinical Investigation, 1984
- Epidermal T lymphocytes and HLA-DR expression in psoriasisBritish Journal of Dermatology, 1984
- T-cell subpopulations in the blood and skin of patients with psoriasisBritish Journal of Dermatology, 1984
- Regulation of Terminal Differentiation of Cultured Mouse Epidermal Cells by lα,25-Dihydroxyvitamin D3*Endocrinology, 1983
- Perioral dermatitis: a 12-year reviewBritish Journal of Dermatology, 1979